Skip to content
OpenCapital
Get started

Zymeworks ZYME Share-based compensation expense related to employee stock plans

Share-based compensation expense related to employee stock plans at other companies

AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
——
Charles River Laboratories logo
Charles River LaboratoriesCRL
——
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
——

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.76B+125%
Enterprise value$1.53B+112%
P/S21.6×+13.2×

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's share-based compensation expense related to employee stock plans.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's share-based compensation expense related to employee stock plans?
Zymeworks (ZYME) reported share-based compensation expense related to employee stock plans of $6.88M in Q1 2026.
How has Zymeworks's share-based compensation expense related to employee stock plans changed year-over-year?
Zymeworks's share-based compensation expense related to employee stock plans increased by 1.3% year-over-year, from $6.79M to $6.88M.
What is the long-term trend for Zymeworks's share-based compensation expense related to employee stock plans?
Over 2 years (2023 to 2025), Zymeworks's share-based compensation expense related to employee stock plans has grown at a 81.7% compound annual growth rate (CAGR), from $8.2M to $27.07M.